A Phase II Study of Biological Response to Dasatinib Treatment in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma.
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2016
At a glance
- Drugs Dasatinib (Primary)
- Indications Malignant melanoma
- Focus Pharmacogenomic; Therapeutic Use
- 19 Aug 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 15 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.